Detlev Ganten
Président chez Charité - Universitätsmedizin Berlin
Profil
Detlev Ganten is currently the Chairman at Charité - Universitätsmedizin Berlin and Max Planck Institute of Colloids & Interfaces.
He is also the Chairman at Max Planck Institute of Molecular Plant Physiology, and a Member-Supervisory Board at Eckert & Ziegler AG and GlycoUniverse GmbH & Co KGaA.
Additionally, he is the President of World Health Summit.
In the past, he served as the Director of Max-Delbrück-Centrum für Molekulare Medizin (MDC) and was a Member-Supervisory Board at Eckert & Ziegler Strahlen- und Medizintechnik AG.
He was also a Member-Administrative Board at Université PSL.
He received his doctorate from McGill University and his undergraduate degree from Eberhard Karls Universität Tübingen.
Postes actifs de Detlev Ganten
Sociétés | Poste | Début |
---|---|---|
Charité - Universitätsmedizin Berlin | Président | 01/01/2005 |
Max Planck Institute of Colloids & Interfaces | Président | 01/01/2010 |
GlycoUniverse GmbH & Co KGaA | Directeur/Membre du Conseil | - |
Eckert & Ziegler AG
Eckert & Ziegler AG Hospital/Nursing ManagementHealth Services Eckert & Ziegler AG is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The private company has a global presence of subsidiaries in several regions and is based in Berlin, DE. With nearly 1,000 employees, the German company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The CEO of the company is Andreas Eckert. | Directeur/Membre du Conseil | - |
World Health Summit | President | 01/01/2009 |
Max Planck Institute of Molecular Plant Physiology | Président | - |
Anciens postes connus de Detlev Ganten
Sociétés | Poste | Fin |
---|---|---|
ECKERT & ZIEGLER SE | Directeur/Membre du Conseil | 29/05/2019 |
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Directeur/Membre du Conseil | 01/01/2004 |
Université PSL | Directeur/Membre du Conseil | - |
Formation de Detlev Ganten
McGill University | Doctorate Degree |
Eberhard Karls Universität Tübingen | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Sociétés cotées | 1 |
---|---|
ECKERT & ZIEGLER SE | Health Technology |
Entreprise privées | 5 |
---|---|
Max-Delbrück-Centrum für Molekulare Medizin (MDC)
Max-Delbrück-Centrum für Molekulare Medizin (MDC) Miscellaneous Commercial ServicesCommercial Services Max-Delbrück-Centrum für Molekulare Medizin operates as a biomedical research institute. It engages in translating discoveries from molecular research into applications to improve the prevention, diagnosis, and treatment of major human diseases. The company was founded in 1992 and is headquartered in Berlin, Germany. | Commercial Services |
Eckert & Ziegler AG
Eckert & Ziegler AG Hospital/Nursing ManagementHealth Services Eckert & Ziegler AG is a leading specialist in isotope-related components for nuclear medicine and radiation therapy. The private company has a global presence of subsidiaries in several regions and is based in Berlin, DE. With nearly 1,000 employees, the German company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. The CEO of the company is Andreas Eckert. | Health Services |
GlycoUniverse GmbH & Co KGaA | |
World Health Summit | |
Max Planck Institute of Molecular Plant Physiology |